Business
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting Pre...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting\n\n\n\n\n Additional data from the MDNA11 ABILITY-1 trial to be presented at the Annual Meeting\n \n\n\n\n Pre-clinical data on Medicenna’s first-in-class Masked and Tumor Targeted Bifunctional anti-PD1-IL2 Superkine, MDNA113, will also be presented\n \n\n\n TORONTO and HOUSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, announced today that two posters will be presented at the American Association for Cancer Research Annual Meeting 2025 (AACR 2025) taking place April 25-30, 2025 in Chicago, Illinois.\n \n\n The Company will present an update from its Phase 1/2 ABILITY-1 Study evaluating MDNA11, the only long-acting, ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist in clinical development. In addition, pre-clinical data for MDNA113, a novel first-in-class tumor-targeted and tumor-activated bi-functional anti-PD1-IL2 Superkine, will also be presented at the conference.\n \n\n Details for the abstracts and poster presentations are as follows:\n \n\n\n Title:\n \n Interim results from the phase 1/2 ABILITY-1 study of a long-acting ‘beta-enhanced not-alpha’ IL-2 superkine in patients with advanced solid tumors\n \n\n Session Title:\n \n Phase 0 and Phase I Clinical Trials\n \n\n Session Date and Time:\n \n Monday, April 28, 2025; 9:00 AM – 12:00 PM\n \n\n Location:\n \n Poster Section 49\n \n\n Poster Board Number:\n \n 26\n \n\n Abstract Number:\n \n CT047\n \n\n\n Title:\n \n MDNA113: A tumor targeting and conditionally activated anti-PD1-IL2\n \n SK\n \n to enhance the therapeutic index\n \n\n Session Title:\n \n T Cell Engagers and Novel Antibody-Based Therapies\n \n\n Session Date and Time:\n \n Wednesday, April 30, 2025; 9:00 AM -12:00 PM\n \n\n Location:\n \n Poster Section 40\n \n\n Poster Board Number:\n \n 16\n \n\n Abstract Number:\n \n 7330\n \n\n Following the conclusion of the AACR 2025 Meeting, a copy of the posters will be available on the “\n \n Events and Presentations\n \n  ...